New treatments for rheumatoid arthritis. Available and upcoming slow-acting antirheumatic drugs (Q33758853)

29 July 2017

1 reference

title

New treatments for rheumatoid arthritis. Available and upcoming slow-acting antirheumatic drugs (English)

1 reference

29 July 2017

1 reference

K H Fye

1

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 October 1999

1 reference

29 July 2017

published in

Postgraduate Medicine

1 reference

29 July 2017

volume

106

1 reference

29 July 2017

issue

4

1 reference

29 July 2017

page(s)

82-5, 88-90, 92

1 reference

Rheumatoid arthritis. Pathophysiology and implications for therapy

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.1999.10.1.703

Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.1999.10.1.703

Cyclosporin treatment for rheumatoid arthritis: a placebo controlled, double blind, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.1999.10.1.703

A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.1999.10.1.703

Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.1999.10.1.703

Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.1999.10.1.703

Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.1999.10.1.703

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.1999.10.1.703

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.1999.10.1.703

Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.1999.10.1.703

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.1999.10.1.703

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.1999.10.1.703

10.3810/PGM.1999.10.1.703

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference